Objective: To investigate the clinical efficacy of Monteiukast and to explore its balance regulation mechanism of Monteiukast on Thl/Th2 cell function of peripheral blood in asthmatic children. Methods: 78 cases of children with bronchia] asthma were randomly divided into treatment group and control group in our hospital from December 2008 to December 2010, 39 cases in each group. Oxygen uptake, relieving asthma, anti-inflammatory, anti-infection and other basic treatment were given to both groups, thus Monteiukast tablets 4 mg/d, orally, once a day for three months were given to the treatment group on the basis of basic treatment. IL--4, TFN-7 levels and IFN-7/TL-4 ratio changes before and after 3 months treatment were compared, the total efficiency of the two groups were compared, and the disappearance time of cough, asthma and wheezing sound were observed in the two groups. Results: The IFN-7 level of treatment group [(41.45± 6.61) ng/L] was significantly higher than thai of control group [(46.57±7.42) ng/L] (￡=2.42, /V0.05); the TL-4 level of treatment group [(41.45~6.61) ng/L] was significantly lower than that of control group [(46.57±7.42)ng/L] (￡-2.68, P<0.05): the IFN-7/IL-4 ratio of treatment group (1.83 ±0.42) was significantly increased than that of control group (1.56 ±0.37) (f-2.13, P<0.05). The total effective rate of treatment group was 92-31%, and the total efficiency of control group was 74-36%, the difference was statistically significant (x2~12.537, P<0.01). Ihe disappearance time of cough, asthma and wheezing sound of treatment group [(2.68±1.15), (5.19±1.25), (4.17±1.75) d)] were significantly shorter than those of control group [(4.43 ± 1.27), (6.70±1.63), (6.25±1.64) d] (￡=2.35, 2.14, 2-41, /V0.01). Conclusion: Monteiukast in the treatment of patients with bronchial asthma is effective and safe, which can significantly improve the clinical symptoms and signs. The mechanism may relate to the balance regulation of Thl/Th2 cell function in children with asthma.%目的:探讨孟鲁司特的临床疗效及其对哮喘患儿外周血Th1/Th2细胞功能平衡的调节作用机制.方法:将2008年12月~2010年12月我院收治的支气管哮喘患儿78例随机分为治疗组和对照组,每组各39例.两组均给予吸氧、平喘、抗炎、抗感染等基础治疗,其中,治疗组在上述治疗的基础上给予孟鲁司特片4 mg/d,口服,1次/d,连用3个月.观察比较两组治疗前和治疗3个月后IL-4、IFN-γ含量及IFN-γ/IL-4比值的变化,对两组的总有效率进行比较,并观察两组咳嗽、喘息及哮鸣音消失时间.结果:治疗组IFN-γ[(76.16±7.42)ng/L]较对照组[(74.53±7.56)ng/L]明显升高(t=2.42,P＜0.05);治疗组IL-4[(41.45±6.61)ng/L]较对照组[(46.57±7.42)ng/L]明显降低(t=2.68,P＜0.05);治疗组IFN-γ/IL-4值(1.83±0.42)较对照组(1.56±0.37)明显上升(t=2.13,P＜0.05);治疗组的总有效率为92.31%,与对照组相比(74.36%),差异有高度统计学意义(χ2=12.537,P＜0.01);治疗组的咳嗽、喘息、哮鸣音消失时间[(2.68±1.15)、(5.19±1.25)、(4.17±1.75)d]均明显短于对照组[(4.43±1.27)、(6.70±1.63)、(6.25±1.64)d],差异有高度统计学意义(t=2.35、2.14、2.41,P＜0.01).结论:孟鲁司特治疗小儿支气管哮喘疗效好,可以明显改善患儿的临床症状与体征,且安全性好,可能与其对支气管哮喘患儿Th1/Th2细胞功能平衡紊乱的调节作用有关.
展开▼
